Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Strange reply, ok
ONPH PAYING FOR IT! SO DOESN'T COST RGBP A DIME!
ONPH PROVIDING THE REQUIRED FINANCING!!!!$$$$$
The current intent is that IND ("Investigational New Drug Application") enabling studies are to be commenced and completed with Regen providing the scientific expertise, laboratory access and modified mRNA and cellular manufacturing needed to complete the studies and ONPH providing the required financing.
5) Establish a social media presence in order to more easily provide updates to our shareholders, the investment community, the scientific community and the public at large.
During the coming months I shall endeavor to achieve the following milestones:
1) Settle all outstanding convertible notes payable in order that the Company will have no convertible instruments outstanding.
2) Hire a Chief Scientific Officer
3) Seek out and enter into alliances, co-development agreements and additional licensing agreements with regard to our proprietary mRNA and NR2F6 portfolios.
4) Obtain OTCQB listing for our securities on the OTC Market.
5) Establish a social media presence in order to more easily provide updates to our shareholders, the investment community, the scientific community and the public at large.
Thank you for your past and continued patience as we move the Company forward. I look forward to receiving shareholder input and can be reached at david.koos@regenbiopharma.com.
Sincerely,
David Koos
RGBP TWITTER ACCOUNT
https://mobile.twitter.com/theregenbio
ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to work jointly to fast track the development of therapeutic uses related to treatment in humans with pancreatic cancer of Regen's patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES ("MRNA Vaccines").
In April of 2021 ONPH was granted an exclusive right and license for the development and commercialization of the MRNA Vaccines for the treatment in humans of pancreatic cancer.
The current intent is that IND ("Investigational New Drug Application") enabling studies are to be commenced and completed with Regen providing the scientific expertise, laboratory access and modified mRNA and cellular manufacturing needed to complete the studies and ONPH providing the required financing
LOTSASHARESBEINGACCUMULATEDDOWNHERE
The current intent is that IND ("Investigational New Drug Application") enabling studies are to be commenced and completed with Regen providing the scientific expertise, laboratory access and modified mRNA and cellular manufacturing needed to complete the studies and ONPH providing the required financing
ONPH PROVIDING THE REQUIRED FINANCING!
RGBP NEWS! NDA! RGBP! CANARY/CORNELL! Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials.
During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.
Now your talkin
LOTSASHARESBEINGACCUMULATEDDOWNHERE!
We will find out soon enough! Green pastures ahead for RGBP!
BOOM SHAKALAKA!
Who cares, wrong board, this is RGBP!
Sweet!
There is a good reason for that!!!!!!!!
That was due to stock split
Yes, very good sign indeed
Its in the press release
Too bad, it isnt. lol ONPH has some heavy investors.
If the weekly chart is any indication, 2 weeks
ONPH PROVIDING THE REQUIRED FINANCING!
(OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to work jointly to fast track the development of therapeutic uses related to treatment in humans with pancreatic cancer of Regen's patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES ("MRNA Vaccines").
RGBP Partner ONPH UP Big Time! RGBP NExt!
ONPH providing the required financing
The current intent is that IND ("Investigational New Drug Application") enabling studies are to be commenced and completed with Regen providing the scientific expertise, laboratory access and modified mRNA and cellular manufacturing needed to complete the studies and ONPH providing the required financing
So you think RGBP has $50 million dollars?
RGBP NEWS! NDA! RGBP! CANARY/CORNELL! Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials.
During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.
Me thinks so toooooo
RGBP/Cornell NDA! I CAN FEEL IT! RGBP! CANARY/CORNELL! Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials.
During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.
OH YEAH!
OF COURSE!
Your Welcome!
ALMOST THERE PEEPS! RGBP! CANARY/CORNELL! Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials.
During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.
Well, they really are keeping this at .01